glp-1 drugs while breastfeeding and Breastfeeding: Safety Evidence and Clinical Consider... – PlexusDx semaglutide during breastfeeding There's growing
Description
11.Novo Nordisk Internet
95% CI 0.03 to 0.66
Review the latest terms on the official website, as policies may be updated
The results obtained suggested that SGLT2is and GLP-1RAs are more effective on mortality and major adverse cardiovascular events (MACEs) compared to DPP-4is
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
These agents have been shown to reduce A1C (by 0.81.6%), body weight (by 13 kg), blood pressure, and lipids
